IBI397 or Its Combination Therapies in Patients With Advanced Malignancies
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this phase Ia/Ib Study to Evaluate the Safety, Tolerability,
Pharmacokinetics and Preliminary Efficacy of IBI397 or its Combination Therapies in Patients
with Advanced Malignancies